Equity in Access to Novel Cancer Therapies Under National Health Insurance Schemes
DOI:
https://doi.org/10.5281/zenodo.22656397Keywords:
health technology assessment, managed-entry agreements, cancer drug access, cost-effectiveness threshold, health equityAbstract
Background: Novel cancer therapies, including immune checkpoint inhibitors, chimeric antigen receptor T-cell (CAR-T) therapies,
and molecularly targeted agents, have produced substantial survival gains but carry acquisition costs that strain the
cost-effectiveness and budget-impact assessments national health insurance schemes use to decide reimbursement. Objective: To
synthesize peer-reviewed evidence on how national health insurance and reimbursement architecture shapes equitable access to
novel cancer therapies across countries and within insured populations. Methods: A narrative review of peer-reviewed literature
identified through targeted PubMed/MEDLINE and Crossref searches, with each candidate source individually verified against its
publisher or bibliographic record before inclusion. Findings were organized thematically around cost-effectiveness threshold
methodology, managed-entry and risk-sharing agreements, cross-country and cross-income disparities in access, and patient-level
financial toxicity within nominally covered populations. Findings: Cost-effectiveness thresholds lack a rigorous empirical basis and
are applied largely unmodified to orphan and cell-based oncology therapies for which the evidence base is systematically thinner,
producing inconsistent reimbursement outcomes across similar submissions. Managed-entry agreements, the principal policy
response to resulting uncertainty, are unevenly available across systems as a function of institutional and analytical capacity
rather than clinical need. Time to patient-level reimbursement after regulatory approval varies from months to several years even
within the European Union, while access disparities between high-income and low- and middle-income countries are considerably
larger and are compounded by diagnostic-funding gaps and treatment-center infrastructure shortfalls. Financial toxicity persists
within nominally covered populations, including under Medicare in the United States, indicating that formal reimbursement status
alone is an insufficient equity metric. Conclusions: Equitable access to novel cancer therapies depends jointly on value-assessment
methodology, managed-entry agreement capacity, and patient cost-sharing design; national health insurance schemes and
policymakers should address these as jointly determined equity levers rather than as separate technical problems.
References
Lee D, McCarthy G, Saeed O, Allen R, Malottki K, Chandler F (2023) The challenge for orphan drugs remains: three case studies demonstrating the impact of changes to NICE methods and processes and alternative mechanisms to value orphan products. PharmacoEconomics Open, 7(2):175-187, DOI:10.1007/s41669-022-00378-8.
Blonda A, Denier Y, Huys I, Simoens S (2021) How to value orphan drugs? A review of European value assessment frameworks. Frontiers in Pharmacology, 12:631527, DOI:10.3389/fphar.2021.631527.
Ruff P, Al-Sukhun S, Blanchard C, Shulman LN (2016) Access to cancer therapeutics in low- and middle-income countries. American Society of Clinical Oncology Educational Book, 35:58-65, DOI:10.1200/EDBK_155975.
Lopes G Jr, de Souza JA, Barrios C (2013) Access to cancer medications in low- and middle-income countries. Nature Reviews Clinical Oncology, 10(6):314-322, DOI:10.1038/nrclinonc.2013.55.
Tfayli AH, El-Halabi LN, Khuri FR (2025) Global disparities in cancer care: bridging the gap in affordability and access to medications between high and low-income countries. Cancer, 131(1):e35590, DOI:10.1002/cncr.35590.
Cameron D, Ubels J, Norström F (2018) On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review. Global Health Action, 11(1):1447828, DOI:10.1080/16549716.2018.1447828.
Shih YT, Pan IW, Teich N (2022) Global challenges in access to and implementation of precision oncology: the health care manager and health economist perspective. American Society of Clinical Oncology Educational Book, 42:429-437, DOI:10.1200/EDBK_359650.
Pauwels K, Huys I, Vogler S, Casteels M, Simoens S (2017) Managed entry agreements for oncology drugs: lessons from the European experience to inform the future. Frontiers in Pharmacology, 8:171, DOI:10.3389/fphar.2017.00171.
Owat P, Sooksriwong C, Ratanabunjerdkul H, Phodha T (2026) Comparative cost evaluation of managed entry agreement techniques using real-world data from high-cost anticancer drugs in Thailand. Journal of Market Access & Health Policy, 14(1):17, DOI:10.3390/jmahp14010017.
Nieto-Gómez P, Castaño-Amores C (2024) Factors influencing the reimbursement of cancer drugs in Europe: a scoping review. Journal of Evaluation in Clinical Practice, 30(8):1546-1555, DOI:10.1111/jep.14080.
Post HC, Schutte T, van Oijen MGH, van Laarhoven HWM, Hollak CEM (2023) Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries. ESMO Open, 8(2):101208, DOI:10.1016/j.esmoop.2023.101208.
Vancoppenolle JM, Franzen N, Koole SN, Retèl VP, van Harten WH (2024) Differences in time to patient access to innovative cancer medicines in six European countries. International Journal of Cancer, 154(5):886-894, DOI:10.1002/ijc.34753.
Hofmarcher T, Charalambous A, Normanno N, Szmytke E, Wilking N (2025) Access to novel cancer medicines in Europe: inequities across countries and their drivers. ESMO Open, 10(10):105810, DOI:10.1016/j.esmoop.2025.105810.
Cardone C, Arnold D (2023) The cancer treatment gap in lower- to middle-income countries. Oncology, 101(Suppl 1):2-4, DOI:10.1159/000530416.
de Souza JA, Hunt B, Asirwa FC, Adebamowo C, Lopes G (2016) Global health equity: cancer care outcome disparities in high-, middle-, and low-income countries. Journal of Clinical Oncology, 34(1):6-13, DOI:10.1200/JCO.2015.62.2860.
Cai JX, Wang SY, Hu H, Ung COL, Li FX, Lin TF, Luo SF, Song HB, Yang ZR, Tang JL, Meng WH (2025) Disparities in the access to immune checkpoint inhibitors approved in the United States, the European Union and mainland China: a serial cross-sectional study. BMJ Public Health, 3(1):e001995, DOI:10.1136/bmjph-2024-001995.
Jenei K (2026) Access to CAR T-cell therapy across diverse global markets. Blood, 147(14):1509-1510, DOI:10.1182/blood.2025032585.
Chung AP, Shafrin J, Vadgama S, Hurley K, Perales MA, Alsfeld LC, Muthukrishnan S, Patel AR, Shah GL, Maziarz RT (2025) Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis. Blood Advances, 9(18):4727-4735, DOI:10.1182/bloodadvances.2024015634.
Tran TH, Kim HSJ (2026) Comparative economic evaluations of CAR-T therapies for relapsed or refractory diffuse large B-cell lymphoma: a systematic review. PharmacoEconomics, 44(3):287-298, DOI:10.1007/s40273-025-01566-0.
Narang AK, Nicholas LH (2017) Out-of-pocket spending and financial burden among Medicare beneficiaries with cancer. JAMA Oncology, 3(6):757-765, DOI:10.1001/jamaoncol.2016.4865.
Parikh DA, Ragavan M, Dutta R, Garnet Edwards J, Dickerson J, Maitra D, Aggarwal S, Lee FC, Patel MI (2021) Financial toxicity of cancer care: an analysis of financial burden in three distinct health care systems. JCO Oncology Practice, 17(10):e1450-e1459, DOI:10.1200/OP.20.00890.
